MOPEAD project

MOPEAD project: Early detection of

Alzheimer's disease in the

hands of the patient


  • EU invests on research to identify efficient models of early diagnosis of Alzheimer's, through patient engagement.

  • The IMI grants to Fundació ACE the leadership of MOPEAD, endowed with about 4 M. euros, after a competitive evaluation system.

  • MOPEAD will analyze the effectiveness of different systems of citizen engagement in the diagnosis of Alzheimer's, including Fundació ACE's model. 2,000 people will participate in this process.


The ACE Foundation - Barcelona Alzheimer Treatment & Research Center has been selected by the IMI (Innovative Medicines Initiative) - public-private partnership between the EU and the European Federation of Pharmaceutical Industry Associations (EFPIA) - to lead the MOPEAD project, A novel research that aims to consolidate an early diagnosis system for Alzheimer's.

The MOPEAD (Models of Patient Engagement for Alzheimer's Disease) project is a European initiative that wants to give the citizen an active role in the early detection of Alzheimer's disease. The IMI will allocate 4 M. euros to evaluate the systems of involvement and participation of the patient that may be effective for the early diagnosis of the disease.

The objective of the MOPEAD project, according to its principal investigator, Mercè Boada, is to sensitize citizens and increase their participation in the diagnosis. This will also help identify unknown cases. The results will provide new clinical data on the disease at an early stage, which will contribute to the definition of novel therapeutic interventions to arrest Alzheimer's disease.

People who are diagnosed precociously live at a time when their cognitive abilities still allow them to decide on their heritage, their legal guardians, or on how and where they want to live in the advanced stages of the disease.

According to Dr. Octavio Rodríguez, Fundació ACE's neurologist, "early diagnosis is cost-effective for the health system because it saves the state money and can reduce suffering, additional costs and burden of disease for families."

For approximately 3 years, the research will test the effectiveness of four models of citizen participation: an online questionnaire, the Fundació ACE's Open Days, a 10-minute test conducted by primary care physicians and a neuropsychological test for patients diagnosed with type 2 diabetes, considered a risk factor for Alzheimer's disease.

The results of the MOPEAD will allow to identify and establish, at European level, the most appropriate model to facilitate citizens' access, with mild cognitive impairment or memory complaints, to a diagnosis of the disease at a very early stage.

Exporting to Europe ACE's model of early diagnosis

At the European level, one of the current challenges of Alzheimer's is to raise awareness of the importance of memory complaints, the need to revise it for prevention and the risks of detecting the disease too late.

Fundación ACE, a pioneer in raising awareness for the promotion of early diagnosis, launched in 2008, the Open Doors Day. With the slogan "If we look at the tension, cholesterol and sugar... Why not the memory?",

Open Days are intended for people over 55 who voluntarily desan make a valuation of memory, language and other Cognitive functions through the neuropsychological battery that Fundació ACE uses in the diagnostic process.

The aim of this initiative is to raise the awareness of the population, apparently healthy at the cognitive level, that it is important to know their mental performance and, if they have subjective memory complaints or cognitive impairment, Alzheimer's can be detected taking into account the importance of prevention and early diagnosis.

In addition to contributing to this model of citizen participation in the early detection of the disease, Fundació ACE will coordinate this clinical research project in which about 2,000 patients will participate.

The entities participating in MOPEAD are, in addition to Fundació ACE, Eli Lilly Company Ltd, ASDM Consulting, and AstraZeneca AB. The European Institute of Women's Health, GMV Soluciones Globales Internet SAU, Karolinska Institute, KITE Innovation (Europe) Ltd, Spomincica-Alzheimer Slovenia, Cologne University Hospital, Ljubljana University Medical Center, Vall D'Hebron-Institut University Hospital Recerca, Stichting VUmc and Alzheimer Europe.

Nowadays, about 35 million people are affected by Alzheimer's disease worldwide. The number is expected to increase with the aging of society. It is expected that by 2050 the figure will have increased to 115 million people affected by this disease, making it one of the most important in the 21st century. Currently, in the Spanish State some 600,000 people suffer from Alzheimer's and it is estimated that by 2050 there will be 1.5 million patients.

Public-private collaboration

The IMI (Innovative Medicines Initiative) is a public-private consortium (PPP) between the EU and the European Federation of Pharmaceutical Industry Associations (EFPIA) - a representative body of the pharmaceutical industry in Europe.

It was created in 2008 to boost pharmaceutical innovation in Europe and accelerate the development of more effective and safe medicines. With a budget of 2 trillion euros, part of IMI's action is to support research projects that foster networks of industrial and academic experts. Its aim is to boost pharmaceutical innovation in Europe.